Berlin’s Apheris and Ginkgo bring pharma giants together to train AI on 10,000 antibodies

What happened

Ginkgo Datapoints and Berlin-based Apheris today announced that the Antibody Developability Consortium has kicked off with its founding members. Members provide privacy-preserving access to their proprietary data and, in return, receive higher-performing models with a broader applicability domain.

The Consortium is a new industry collaboration designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field’s largest standardised antibody developability dataset. Apheris’ expertise lies in driving the adoption of AI models within pharmaceutical drug programs, customising and fine-tuning (further training of an existing model for a narrower job) them on each company’s proprietary chemistry and biology so they perform where public data cannot reach. Developability challenges can prevent otherwise promising antibody candidates from progressing efficiently toward patients.

Key facts

• Ginkgo Datapoints and Berlin-based Apheris today — announced: that the Antibody Developability Consortium has kicked off with its founding members